Abstracts tagged "Biologicals"

Abstract Number: 2278 • ACR Convergence 2024
Similar Etanercept Adherence in Individuals with Rheumatic Disease Initiating Originator and Biosimilar: A Population-Based Study
Olga Tsyruk¹, Marina Birck², Sasha Bernatsky², Luck Lukusa³, Denis Choquette⁴, Gilles Boire⁵ and Walter Maksymowych⁶, ¹McGill University, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴Rhumadata™, Montreal, QC, Canada, ⁵Retired, Sherbrooke, QC, Canada, ⁶University of Alberta, Edmonton, AB, Canada
Background/Purpose: Treatment adherence is crucial to optimizing outcomes in rheumatic diseases. Suboptimal adherence is common with inflammatory and chronic diseases, often treated with biologics, including…
Abstract Number: 2482 • ACR Convergence 2024
Long-Term Safety of Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA): Pooled Results from Two Open-Label Extension Studies
Gerhard Wolff¹, Michael E Wechsler², Jared Silver³, Robert Price⁴, Rejina Verghis⁵, Peter Weller⁶, Peter Merkel⁷, Thomas Corbridge⁸ and Paneez Khoury⁹, ¹Clinical Development-Respiratory, GSK, Collegeville, ²Department of Medicine, National Jewish Health, Denver, CO, ³US Medical Affairs-Respiratory, GSK, Durham, ⁴Biostatistics, GSK, Stevenage, United Kingdom, ⁵Biostatistics, Development Respiratory, GSK, Brentford, United Kingdom, ⁶Beth Israel Deaconess Medical Center, Department of Medicine, Division of Allergy and Inflammation, Harvard Medical School, Boston, MA, ⁷Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, ⁸US Value Evidence and Outcomes, GSK, Durham, NC, ⁹National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: The 52-week Phase III MIRRA trial demonstrated the safety and efficacy of anti-IL-5 mepolizumab in patients with EGPA. However, longer-term safety data are limited.…
Abstract Number: 0013 • ACR Convergence 2024
Preclinical Polypharmacology of S-1117, a Novel Engineered Fc-fused IgG Degrading Enzyme, for Chronic Treatment of Autoantibody-mediated Diseases
Julia Manasson¹, Liliana Sanmarco², Alex Pellerin², Jordan Anderson², Nathan Rollins², Tobias Green², Agustin Plasencia², Andita Newton², Ryan Peckner², Yi Xing², Heather Vital³, Nathan Higginson-Scott², John Sundy⁴, Kevin L. Otipoby² and Ivan Mascanfroni², ¹Seismic Therapeutic, New York, NY, ²Seismic Therapeutic, Watertown, MA, ³Seismic Therapeutic, Lexington, MA, ⁴Seismic Therapeutic, Chapel Hill, NC
Background/Purpose: Pathogenic autoantibodies are key effectors of inflammation, promoting immune cell responses that cause tissue damage in autoantibody-mediated diseases such as idiopathic inflammatory myopathies, lupus…
Abstract Number: 0399 • ACR Convergence 2024
Eosinophilia and Exposure to IL-1 and IL-6 Blocking Biologic Medications in a Systemic Juvenile Idiopathic Arthritis Patient Cohort
Rachel Dickey¹, Doel Dhar², Srushti Gangireddy³, Henry H. Ong³, Wei-Qi Wei³ and Anna Patrick³, ¹Lipscomb University College of Pharmacy, Athens, TN, ²Monroe Carell Jr Children's Hospital at Vanderbilt, Nashville, TN, ³Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is a severe disease with symptoms of fevers, rash, and arthritis. High levels of the inflammatory cytokines interlukin-1 (IL-1)…
Abstract Number: 0523 • ACR Convergence 2024
Distinct Peripheral Blood Immune Cell Sub-population Signatures at Baseline of Tofacitinib or Adalimumab Initiation Are Associated to Clinical Responses at 6 Months
Panagiota Goutakoli¹, Eirini Sevdali¹, Elpida Neofotistou-Themeli¹, Argyro Repa², Nestor Avgoustidis³, Sofia Pitsigavdaki⁴, Eleni Kalogiannaki², George Bertsias⁵, Nikolaos Paschalidis⁶, Panayotis Verginis⁷ and Prodromos Sidiropoulos⁸, ¹University of Crete, Laboratory of Rheumatology, Autoimmunity and Inflammation, Heraklion, Greece, ²University Hospital, Rheumatology, Clinical Immunology, Heraklion, Greece, ³University Hospital, Rheumatology and Clinical Immunology,, Heraklion, Greece, ⁴Rheumatology and Clinical Immunology, University of Crete School of Medicine, Heraklion, Greece, Heraklion, Greece, ⁵Laboratory of Rheumatology, Autoimmunity and Inflammation. University Hospital, Rheumatology, Clinical Immunology, Heraklion, Greece, ⁶Biomedical Research Foundation, Academy of Athens, Athens, Greece, ⁷Medical School, University of Crete, Heraklion, Crete, Greece, ⁸University of Crete, Laboratory of Rheumatology, Autoimmunity and Inflammation. University Hospital, Rheumatology, Clinical Immunology. Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology, Heraklion, Greece, HERAKLIO, Greece
Background/Purpose: Biomarkers to predict response to tofacitinib or adalimumab are not clinically available. Herein we aimed to characterize peripheral blood immune cell subsets with a…
Abstract Number: 0594 • ACR Convergence 2024
Real-world Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-17 Inhibitors: A 16-week Multicenter Retrospective Review
Siddhartha Sood¹, Alexander Rimke², Brian Rankin³, Abrahim Abduelmula⁴, jorge Georgakopoulos⁴, Khalad Maliyar⁴, Ahmed Bagit⁵, Fernejoy Leung⁶, Alim Devani⁶, Ronald Vender⁷, Jensen Yeung⁴ and Vimal Prajapati³, ¹Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada, ²Dermatology Research Institute, Calgary, AB, Canada, ³Division of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada, ⁴Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Canada, ⁵Temerty Faculty of Medicine, University of Toronto, Toronto, Canada, ⁶Skin Health & Wellness Centre, Calgary, AB, Canada, ⁷Division of Dermatology, Department of Medicine, McMaster University, Hamilton, Canada
Background/Purpose: While biologic switching is common in routine clinical practice, limited information exists on switching within class from another IL-17i to bimekizumab. We conducted a…
Abstract Number: 0858 • ACR Convergence 2024
Baricitinib in Early Polymyalgia Rheumatica (BACHELOR Study)
Alain SARAUX¹, Guillermo CARVAJAL ALEGRIA², Emmanuelle Dernis³, christian roux⁴, Christophe Richez⁵, Alice TISON⁶, Baptiste Quere⁷, Sandrine Jousse-Joulin⁸, Dewi Guellec⁷, Thierry Marhadou⁹, Patrice Kervarrec⁷, Divi Cornec¹⁰, Catherine Le Henaff⁷, Sandra Lesven⁷, nowak emmanuel⁷, Aghiles Souki⁷ and Valerie Devauchelle¹¹, ¹CHU Brest, Brest, France, ²CHRU de Tours, Tours, France, ³CH LE MANS, LE MANS, Pays de la Loire, France, ⁴rheumatology department, university Cote d'Azur, nice, France, ⁵Université de Bordeaux, Bordeaux, France, ⁶CHU de la Cavale Blanche, Brest, France, Brest, France, ⁷Centre Hospitalier Regional Universitaire (CHU) de Brest, Brest, France, ⁸cavale blanche hospital, brest, France, ⁹CHU Cavale Blanche, Brest, France, ¹⁰University of Brest, Brest, France, ¹¹UBO, Brest, France
Background/Purpose: Moderate glucocorticoids (GCs) improve nearly all cases of polymyalgia rheumatica (PMR) but related adverse events are common in senior patients. The purpose of this…
Abstract Number: 1135 • ACR Convergence 2024
Deucravacitinib in Plaque Psoriasis: 4-Year Efficacy Results by Prior Biologic Treatment in the Phase 3 POETYK PSO-1, PSO-2, and Long-Term ExtensionTrials
Richard Warren¹, April W. Armstrong², Shinichi Imafuku³, Akimichi Morita⁴, Carle Paul⁵, Matthias Augustin⁶, Thierry Passeron⁷, Leon Kircik⁸, Eleni Vritzali⁸, Thomas Scharnitz⁹, Georgene Schroeder⁹, Subhashis Banerjee¹⁰ and Bruce Strober¹¹, ¹Dermatology Centre, Northern Care Alliance NHS Foundation Trust and NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²University of California Los Angeles, Los Angeles, ³Fukuoka University Hospital Faculty of Medicine, Fukuoka, Japan, ⁴Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ⁵Toulouse University and CHU, Toulouse, France, ⁶Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ⁷Université Côte d’Azur, University Hospital of Nice, Nice, France, ⁸Icahn School of Medicine at Mount Sinai, New York, NY, ⁹Bristol Myers Squibb, Princeton, ¹⁰Bristol Myers Squibb, Princeton, NJ, ¹¹Department of Dermatology, Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell, CT
Background/Purpose: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with moderate…
Abstract Number: 1460 • ACR Convergence 2024
Safety and Effectiveness of 97 Combinations of Targeted Therapies in Immune Mediated Inflammatory Diseases : Preliminary Data from the COMBATT Registry
Lou Kawka¹, Jacques-Eric Gottenberg², Jérôme Avouac³, OLIVIER BROCQ⁴, GILLES HAYEM⁵, Xavier Mariette⁶, Alain Meyer⁷, BENOIT FLACHAIRE⁸, OLIVIER FOGEL⁹, ARTHUR GANDIOLLE¹⁰, MANON LESTURGIE¹¹, JEAN-FRANCOIS KLEINMANN¹², Samira Ahmed Yahia¹³ and Thao Pham¹⁴, ¹Hôpital Universitaire de Strasbourg, Strasbourg, Alsace, France, ²Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ³Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ⁴Service de Rhumatologie, centre hospitalier Princesse-Grâce, Monaco, Monaco, ⁵Groupe Hospitalier Paris Saint-Joseph, Paris, France, ⁶Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, ⁷UR3072, Physiology Department, Rheumatology Department, University Hospital of Strasbourg, Strasbourg, France, ⁸Aix Marseille University, Marseille, France, ⁹AP-HP, Paris, France, ¹⁰Strasbourg University Hospital, Strasbourg, France, ¹¹Cochin hospital, Paris, France, ¹²Rheumatology department strasbourg, Strasbourg, France, ¹³Hôpital Universitaire de Strasbourg, Strasbourg, France, ¹⁴Assistance Publique-Hôpitaux de Marseille, Marseille, France
Background/Purpose: This study aimed to evaluate the clinical scenarios in which clinicians initiate cTT, as well as the safety and effectiveness of cTT in patients…
Abstract Number: 1554 • ACR Convergence 2024
Belimumab Increases SLE Responder Index-4 Response Rates versus Placebo in Early Active Systemic Lupus Erythematosus: A Large Integrated Analysis of Belimumab Trials
Karen Costenbader¹, Joan Merrill², Marta Mosca³, Holly Quasny⁴, Christine Henning⁵, Steven Bloom⁶, Julia Harris⁶, Ciara O’Shea⁷, Tatsuya Atsumi⁸ and Ronald van Vollenhoven⁹, ¹Brigham and Women’s Hospital, Division of Rheumatology, Inflammation and Immunity, Harvard Medical School, Boston, MA, ²Oklahoma Medical Research Foundation, Arthritis & Clinical Immunology Program, Oklahoma City, OK, ³University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy, ⁴GSK, Clinical Sciences, Durham, NC, ⁵GSK, Global Medical Affairs, Durham, NC, ⁶GSK, Immunology Biostatistics, Brentford, United Kingdom, ⁷GSK, Rheumatology, Global Medical Affairs, Dublin, Ireland, ⁸Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, ⁹Amsterdam Rheumatology and Immunology Center and Amsterdam University Medical Centers, Department of Rheumatology, Amsterdam, Netherlands

Background/Purpose: There are benefits of early treatment for autoimmune diseases; however, data are not available for patients (pts) with SLE as there is no definition…
Abstract Number: 2012 • ACR Convergence 2024
Safety, Tolerability and Efficacy of Pegloticase Administered with a Shorter Infusion Duration in Subjects with Uncontrolled Gout Receiving Methotrexate: Primary Findings of the AGILE Open-label Trial
Orrin Troum¹, John Botson², Fang Fang³, Katie Obermeyer³, Supra Verma³ and Brian LaMoreaux⁴, ¹Providence Health Care/Doctor's of St John's (MDSJ) Santa Monica, CA, Santa Monica, CA, ²Orthopedic Physicians Alaska, Anchorage, AK, ³Amgen, Inc., Thousand Oaks, CA, ⁴Amgen, Inc., Deerfield, IL
Background/Purpose: Pegloticase, infused every 2 weeks over ≥2 hrs, lowers serum urate (SU) in patients with refractory gout. Decreasing infusion time is expected to improve…
Abstract Number: 2281 • ACR Convergence 2024
Assessment of Comparative Efficacy Between Candidate Biosimilar AVT05 and Reference Golimumab
Monica Luque¹, Kristina Zhelyazkova¹, Laxmikant Vashishta², Masna Rai³, Abid Sattar⁴, Richard Bucknall⁴, Steffen Leutz³ and FAUSTO BERTI¹, ¹Alvotech, Zürich, Switzerland, ²Alvotech, Bangalore, India, ³Alvotech, Jülich, Germany, ⁴Alvotech, London, United Kingdom
Background/Purpose: Golimumab is a safe and effective treatment for RA. Biosimilars to the reference product (RP) may make treatment more accessible. We assessed comparable efficacy…
Abstract Number: 2515 • ACR Convergence 2024
Upadacitinib for Refractory Behçet’s Syndrome: A Multi-center, Prospective, Open-label, Pilot Study
Weiyi Xia¹, Jiachen Li¹, Tian Liu¹ and Yuhui Li², ¹Peking University People’s Hospital, Beijing, China, ²Peking University, BeiJing, China
Background/Purpose: The aim of this prospective cohort study is to evaluate the efficacy and safety of Janus kinase (JAK) inhibitor upadacitinib in refractory Behçet’s Syndrome…
Abstract Number: L14 • ACR Convergence 2023
Efficacy and Safety of Benralizumab Compared with Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Patients Receiving Standard of Care Therapy: Phase 3 MANDARA Study
Michael Wechsler¹, Parameswaran Nair², Benjamin Terrier³, Bastian Walz⁴, Arnaud Bourdin⁵, David Jayne⁶, David Jackson⁷, Florence Roufosse⁸, Lena Börjesson Sjö⁹, Ying Fan¹⁰, Maria Jison¹⁰, Christopher McCrae¹¹, Sofia Necander⁹, Anat Shavit¹², Claire Walton¹² and Peter Merkel¹³, ¹National Jewish Health, Denver, CO, ²McMaster University, Hamilton, ON, Canada, ³Cochin Hospital, Paris, France, ⁴University of Tübingen, Kirchheim-Teck, Germany, ⁵University of Montpellier, CHU Montpellier, INSERM, Montpellier, Montpellier, France, ⁶Addenbrooke's Hospital, Cambridge, United Kingdom, ⁷Guy's Severe Asthma Centre, School of Immunology & Microbial Sciences, King's College London,, London, United Kingdom, ⁸Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium, ⁹Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ¹⁰Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca,, Gaithersburg, MD, ¹¹Translational Science & Experimental Medicine, Early Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ¹²BioPharmaceutials Medical, AstraZeneca, Cambridge, United Kingdom, ¹³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Eosinophilic inflammation is a key pathophysiological mechanism of eosinophilic granulomatosis with polyangiitis (EGPA). Oral glucocorticoids (OGCs) and immunosuppressants remain the basis for the standard…
Abstract Number: L08 • ACR Convergence 2023
Early Clinical Development of CIT-013, a First in Class NETosis Inhibitor, in a Randomized Phase I Dose Escalation Study in Healthy Volunteers Demonstrating Potent Inhibition of LPS Induced Neutrophil Extracellular Trap Formation
Leonie Middelink¹, Renato Chirivi², Helmuth van Es², Eric Meldrum², Peter van Zandvoort², Tirza Bruurmijn², Matthijs Moerland³ and Patrick Round², ¹Middelinc., Utrecht, Netherlands, ²Citryll BV, Oss, Netherlands, ³CHDR, Leiden, Netherlands
Background/Purpose: Aberrant Neutrophil Extracellular Traps (NETs) production contributes to the pathophysiology of multiple inflammatory and autoimmune diseases such as Rheumatoid arthritis (RA) Hidradenitis suppurativa (HS),…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].